TELO
Income statement / Annual
Last year (2024), Telomir Pharmaceuticals, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Telomir Pharmaceuticals, Inc. Common Stock's net income was -$16.53 M.
See Telomir Pharmaceuticals, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$3.94 M
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
-$3.94 M
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
Research and Development Expenses |
$2.24 M
|
$1.57 M
|
$833,206.00
|
$126,492.00
|
General & Administrative Expenses |
$9.64 M
|
$600,192.00
|
$20,941.00
|
$11,639.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$9.64 M
|
$600,192.00
|
$20,941.00
|
$11,639.00
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$11.87 M
|
$3.94 M
|
$854,147.00
|
$138,131.00
|
Cost And Expenses |
$0.00
|
$3.94 M
|
$854,147.00
|
$138,131.00
|
Interest Income |
$48,000.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
-$4.34 M
|
$1.64 M
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$0.00
|
-$7.49 M
|
$854,147.00
|
$138,131.00
|
EBITDA |
$0.00 |
-$11.43 M |
-$854,147.00 |
-$138,131.00 |
EBITDA Ratio |
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$0.00
|
-$9.13 M
|
$0.00
|
$0.00
|
Income Before Tax |
-$16.53 M
|
-$13.07 M
|
-$854,147.00
|
-$138,131.00
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
Income Tax Expense |
-$16.53 M
|
$0.00
|
-$854,144.00
|
-$138,132.00
|
Net Income |
-$16.53 M
|
-$13.07 M
|
-$854,147.00
|
-$138,131.00
|
Net Income Ratio |
0
|
0
|
0
|
0
|
EPS |
-0.56 |
-0.44 |
-0.0288 |
-0.0047 |
EPS Diluted |
-0.56 |
-0.44 |
-0.0288 |
-0.0047 |
Weighted Average Shares Out |
$29.54 M
|
$29.61 M
|
$29.61 M
|
$29.61 M
|
Weighted Average Shares Out Diluted |
$29.54 M
|
$29.61 M
|
$29.61 M
|
$29.61 M
|
Link |
|
|
|
|